Qynapse
Qynapse is a neuroscience company founded in Paris, France in 2015, focused on advancing the accuracy and reliability of Central Nervous System (CNS) disease screening and monitoring. Their core offerings include QyScore®, an FDA-cleared and CE-marked neuroimaging software platform that uses AI to generate automated biomarkers for diagnosis and patient monitoring. They also offer QyPredict®, a research-use-only platform leveraging machine learning to predict disease trajectories. Qynapse serves clinicians, patients, pharmaceutical companies, and payers, aiming to provide peace of mind through trusted, precise results in the diagnosis and treatment of CNS disorders like Alzheimer's, Multiple Sclerosis, and Parkinson's.
Qynapse
Qynapse is a neuroscience company founded in Paris, France in 2015, focused on advancing the accuracy and reliability of Central Nervous System (CNS) disease screening and monitoring. Their core offerings include QyScore®, an FDA-cleared and CE-marked neuroimaging software platform that uses AI to generate automated biomarkers for diagnosis and patient monitoring. They also offer QyPredict®, a research-use-only platform leveraging machine learning to predict disease trajectories. Qynapse serves clinicians, patients, pharmaceutical companies, and payers, aiming to provide peace of mind through trusted, precise results in the diagnosis and treatment of CNS disorders like Alzheimer's, Multiple Sclerosis, and Parkinson's.
TL;DR
Founded: 2015 (Paris, France)
Core product: QyScore — FDA 510(k)-cleared and CE-marked neuroimaging software
Focus: AI-powered neuroimaging for CNS disease diagnosis, monitoring and trial-readiness
Notable tech: Automated volumetric quantification and imaging biomarkers from brain MRI
Funding signal: Seed round disclosed Jun 24, 2021; investor listed: AGORANOV
Company Overview
Problem Domain
Central Nervous System (CNS) disease diagnosis, monitoring and clinical-trial readiness
Founded
2015
Industry
Biotechnology
Tech Stack
Funding Track Record
Most recent disclosed round per available records
Investor Signal
“AGORANOV(identified as an investor)”